Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 728

1.

Arteriovenous fistula thrombosis is associated with increased all-cause and cardiovascular mortality in haemodialysis patients from the AURORA trial.

Girerd S, Girerd N, Frimat L, Holdaas H, Jardine AG, Schmieder RE, Fellström B, Settembre N, Malikov S, Rossignol P, Zannad F.

Clin Kidney J. 2019 May 11;13(1):116-122. doi: 10.1093/ckj/sfz048. eCollection 2020 Feb.

2.

Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials.

Rossello X, Ferreira JP, Pocock SJ, McMurray JJV, Solomon SD, Lam CSP, Girerd N, Pitt B, Rossignol P, Zannad F.

Eur J Heart Fail. 2020 Feb 19. doi: 10.1002/ejhf.1740. [Epub ahead of print]

PMID:
32077220
3.

Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure).

Stienen S, Ferreira JP, Kobayashi M, Preud'homme G, Dobre D, Machu JL, Duarte K, Bresso E, Devignes MD, López N, Girerd N, Aakhus S, Ambrosio G, Brunner-La Rocca HP, Fontes-Carvalho R, Fraser AG, van Heerebeek L, Heymans S, de Keulenaer G, Marino P, McDonald K, Mebazaa A, Papp Z, Raddino R, Tschöpe C, Paulus WJ, Zannad F, Rossignol P.

Biomarkers. 2020 Feb 16:1-11. doi: 10.1080/1354750X.2020.1727015. [Epub ahead of print]

PMID:
32063068
4.

Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals.

O'Lone E, Howell M, Viecelli AK, Craig JC, Tong A, Sautenet B, Herrington WG, Herzog CA, Jafar TH, Jardine M, Krane V, Levin A, Malyszko J, Rocco MV, Strippoli G, Tonelli M, Wang AY, Wanner C, Zannad F, Winkelmayer WC, Wheeler DC.

Nephrol Dial Transplant. 2020 Feb 10. pii: gfaa008. doi: 10.1093/ndt/gfaa008. [Epub ahead of print]

PMID:
32040154
5.

Distinct Pathological Pathways in Patients With Heart Failure and Diabetes.

Tromp J, Voors AA, Sharma A, Ferreira JP, Ouwerkerk W, Hillege HL, Gomez KA, Dickstein K, Anker SD, Metra M, Lang CC, Ng LL, van der Harst P, van Veldhuisen DJ, van der Meer P, Lam CSP, Zannad F, Sama IE.

JACC Heart Fail. 2020 Jan 31. pii: S2213-1779(19)30868-6. doi: 10.1016/j.jchf.2019.11.005. [Epub ahead of print]

PMID:
32035890
6.

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.

Ter Maaten JM, Martens P, Damman K, Dickstein K, Ponikowski P, Lang CC, Ng LL, Anker SD, Samani NJ, Filippatos G, Cleland JG, Zannad F, Hillege HL, van Veldhuisen DJ, Metra M, Voors AA, Mullens W.

Clin Res Cardiol. 2020 Jan 30. doi: 10.1007/s00392-020-01598-w. [Epub ahead of print]

PMID:
32002631
7.

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes.

Iborra-Egea O, Santiago-Vacas E, Yurista SR, Lupón J, Packer M, Heymans S, Zannad F, Butler J, Pascual-Figal D, Lax A, Núñez J, de Boer RA, Bayés-Genís A.

JACC Basic Transl Sci. 2019 Oct 23;4(7):831-840. doi: 10.1016/j.jacbts.2019.07.010. eCollection 2019 Nov.

8.

Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study.

Lombardi CM, Ferreira JP, Carubelli V, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Voors A, Metra M.

Clin Res Cardiol. 2020 Jan 29. doi: 10.1007/s00392-019-01588-7. [Epub ahead of print]

PMID:
31996990
9.

Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE-HF trial.

Ferreira JP, Duarte K, Woehrle H, Cowie MR, Wegscheider K, Angermann C, d'Ortho MP, Erdmann E, Levy P, Simonds AK, Somers VK, Teschler H, Rossignol P, Koenig W, Zannad F.

ESC Heart Fail. 2020 Jan 17. doi: 10.1002/ehf2.12521. [Epub ahead of print]

10.

Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.

Pellicori P, Ferreira JP, Mariottoni B, Brunner-La Rocca HP, Ahmed FZ, Verdonschot J, Collier T, Cuthbert JJ, Petutschnigg J, Mujaj B, Girerd N, González A, Clark AL, Cosmi F, Staessen JA, Heymans S, Latini R, Rossignol P, Zannad F, Cleland JGF.

Eur J Heart Fail. 2020 Jan 16. doi: 10.1002/ejhf.1716. [Epub ahead of print]

PMID:
31950604
11.

Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study.

Zannad F, Hsu BG, Maeda Y, Shin SK, Vishneva EM, Rensfeldt M, Eklund S, Zhao J.

ESC Heart Fail. 2020 Jan 15. doi: 10.1002/ehf2.12561. [Epub ahead of print]

12.

Predictors of sudden cardiac death in high-risk patients following a myocardial infarction.

Docherty KF, Ferreira JP, Sharma A, Girerd N, Gregson J, Duarte K, Petrie MC, Jhund PS, Dickstein K, Pfeffer MA, Pitt B, Rossignol P, Zannad F, McMurray JJV.

Eur J Heart Fail. 2020 Jan 16. doi: 10.1002/ejhf.1694. [Epub ahead of print]

PMID:
31944496
13.

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.

Serenelli M, Jackson A, Dewan P, Jhund PS, Petrie MC, Rossignol P, Campo G, Pitt B, Zannad F, Ferreira JP, McMurray JJV.

JACC Heart Fail. 2020 Jan 6. pii: S2213-1779(19)30802-9. doi: 10.1016/j.jchf.2019.09.011. [Epub ahead of print]

PMID:
31926854
14.

Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction.

Rossignol P, Duarte K, Girerd N, Karoui M, McMurray JJV, Swedberg K, van Veldhuisen DJ, Pocock S, Dickstein K, Zannad F, Pitt B.

Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1724. [Epub ahead of print]

PMID:
31919958
15.

Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure.

Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman ÅK, Wilk JB, Morley MP, Chaffin MD, Helgadottir A, Verweij N, Dehghan A, Almgren P, Andersson C, Aragam KG, Ärnlöv J, Backman JD, Biggs ML, Bloom HL, Brandimarto J, Brown MR, Buckbinder L, Carey DJ, Chasman DI, Chen X, Chen X, Chung J, Chutkow W, Cook JP, Delgado GE, Denaxas S, Doney AS, Dörr M, Dudley SC, Dunn ME, Engström G, Esko T, Felix SB, Finan C, Ford I, Ghanbari M, Ghasemi S, Giedraitis V, Giulianini F, Gottdiener JS, Gross S, Guðbjartsson DF, Gutmann R, Haggerty CM, van der Harst P, Hyde CL, Ingelsson E, Jukema JW, Kavousi M, Khaw KT, Kleber ME, Køber L, Koekemoer A, Langenberg C, Lind L, Lindgren CM, London B, Lotta LA, Lovering RC, Luan J, Magnusson P, Mahajan A, Margulies KB, März W, Melander O, Mordi IR, Morgan T, Morris AD, Morris AP, Morrison AC, Nagle MW, Nelson CP, Niessner A, Niiranen T, O'Donoghue ML, Owens AT, Palmer CNA, Parry HM, Perola M, Portilla-Fernandez E, Psaty BM; Regeneron Genetics Center, Rice KM, Ridker PM, Romaine SPR, Rotter JI, Salo P, Salomaa V, van Setten J, Shalaby AA, Smelser DT, Smith NL, Stender S, Stott DJ, Svensson P, Tammesoo ML, Taylor KD, Teder-Laving M, Teumer A, Thorgeirsson G, Thorsteinsdottir U, Torp-Pedersen C, Trompet S, Tyl B, Uitterlinden AG, Veluchamy A, Völker U, Voors AA, Wang X, Wareham NJ, Waterworth D, Weeke PE, Weiss R, Wiggins KL, Xing H, Yerges-Armstrong LM, Yu B, Zannad F, Zhao JH, Hemingway H, Samani NJ, McMurray JJV, Yang J, Visscher PM, Newton-Cheh C, Malarstig A, Holm H, Lubitz SA, Sattar N, Holmes MV, Cappola TP, Asselbergs FW, Hingorani AD, Kuchenbaecker K, Ellinor PT, Lang CC, Stefansson K, Smith JG, Vasan RS, Swerdlow DI, Lumbers RT.

Nat Commun. 2020 Jan 9;11(1):163. doi: 10.1038/s41467-019-13690-5.

16.

Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial.

Petutschnigg J, Ferreira JP, Holzendorf V, Trippel TD, Hashemi D, Wachter R, Herrmann-Lingen C, Hasenfuß G, Zannad F, Pieske B, Edelmann F.

Eur J Heart Fail. 2020 Jan 7. doi: 10.1002/ejhf.1723. [Epub ahead of print] No abstract available.

PMID:
31912594
17.

Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.

Sharma A, Vaduganathan M, Ferreira JP, Liu Y, Bakris GL, Cannon CP, White WB, Zannad F.

J Am Heart Assoc. 2020 Jan 7;9(1):e012797. doi: 10.1161/JAHA.119.012797. Epub 2020 Jan 4.

18.

Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial.

Bhatt AS, Vaduganathan M, Patel RB, Fonarow GC, Subacius HP, Konstam MA, Zannad F, Butler J, Greene SJ.

Eur J Heart Fail. 2020 Jan;22(1):164-167. doi: 10.1002/ejhf.1651. Epub 2019 Dec 3. No abstract available.

PMID:
31797490
19.

Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study.

Ferreira JP, Ouwerkerk W, Tromp J, Ng L, Dickstein K, Anker S, Filippatos G, Cleland JG, Metra M, van Veldhuisen DJ, Voors AA, Zannad F.

Eur J Heart Fail. 2020 Jan;22(1):81-89. doi: 10.1002/ejhf.1654. Epub 2019 Dec 2.

PMID:
31793144
20.

Heritability of a resting heart rate in a 20-year follow-up family cohort with GWAS data: Insights from the STANISLAS cohort.

Xhaard C, Dandine-Roulland C, Villemereuil P, Floch EL, Bacq-Daian D, Machu JL, Ferreira JP, Deleuze JF, Zannad F, Rossignol P, Girerd N.

Eur J Prev Cardiol. 2019 Dec 2:2047487319890763. doi: 10.1177/2047487319890763. [Epub ahead of print]

PMID:
31791143
21.

Medical Therapies for Heart Failure With Preserved Ejection Fraction.

Kjeldsen SE, von Lueder TG, Smiseth OA, Wachtell K, Mistry N, Westheim AS, Hopper I, Julius S, Pitt B, Reid CM, Devereux RB, Zannad F.

Hypertension. 2020 Jan;75(1):23-32. doi: 10.1161/HYPERTENSIONAHA.119.14057. Epub 2019 Dec 2.

PMID:
31786973
22.

Bioprofiles and mechanistic pathways associated with Cheyne-Stokes respiration: insights from the SERVE-HF trial.

Ferreira JP, Duarte K, Woehrle H, Cowie MR, Angermann C, d'Ortho MP, Erdmann E, Levy P, Simonds AK, Somers VK, Teschler H, Wegscheider K, Bresso E, Dominique-Devignes M, Rossignol P, Koenig W, Zannad F.

Clin Res Cardiol. 2019 Nov 29. doi: 10.1007/s00392-019-01578-9. [Epub ahead of print]

PMID:
31784904
23.

MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT.

Ferreira JP, Rossello X, Eschalier R, McMurray JJV, Pocock S, Girerd N, Rossignol P, Pitt B, Zannad F.

JACC Heart Fail. 2019 Dec;7(12):1012-1021. doi: 10.1016/j.jchf.2019.08.017.

PMID:
31779922
24.

Renin-angiotensin-aldosterone system and kidney interactions in heart failure.

Ferreira JP, Rossignol P, Zannad F.

J Renin Angiotensin Aldosterone Syst. 2019 Oct-Dec;20(4):1470320319889415. doi: 10.1177/1470320319889415. No abstract available.

25.

Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.

McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer N, Vardeny O, Claggett B, Jhund PS, Solomon SD.

Circulation. 2020 Feb 4;141(5):338-351. doi: 10.1161/CIRCULATIONAHA.119.044491. Epub 2019 Nov 17.

PMID:
31736337
26.

Assessment of Tunisian acceptance to participate in a Clinical Trial.

Stamboul N, Dziri C, Zannad F, Dziri S, Jeribi C, Gaaied A.

Tunis Med. 2019 Apr;97(4):516-518.

27.

Autonomic Nervous System Modulation in Heart Failure: Do We Need Another Trial?

Zannad F.

Circ Heart Fail. 2019 Nov;12(11):e006491. doi: 10.1161/CIRCHEARTFAILURE.119.006491. Epub 2019 Nov 14. No abstract available.

PMID:
31722537
28.

Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment.

Nauta JF, Hummel YM, Tromp J, Ouwerkerk W, van der Meer P, Jin X, Lam CSP, Bax JJ, Metra M, Samani NJ, Ponikowski P, Dickstein K, Anker SD, Lang CC, Ng LL, Zannad F, Filippatos GS, van Veldhuisen DJ, van Melle JP, Voors AA.

Eur J Heart Fail. 2019 Nov 11. doi: 10.1002/ejhf.1632. [Epub ahead of print]

PMID:
31713324
29.

Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF.

Kobayashi M, Voors AA, Girerd N, Billotte M, Anker SD, Cleland JG, Lang CC, Ng LL, van Veldhuisen DJ, Dickstein K, Metra M, Duarte K, Rossignol P, Zannad F, Ferreira JP.

Eur J Intern Med. 2020 Jan;71:62-69. doi: 10.1016/j.ejim.2019.10.017. Epub 2019 Nov 8.

PMID:
31708361
30.

Income level and inequality as complement to geographical differences in cardiovascular trials.

Ferreira JP, Rossignol P, Dewan P, Lamiral Z, White WB, Pitt B, McMurray JJV, Zannad F.

Am Heart J. 2019 Dec;218:66-74. doi: 10.1016/j.ahj.2019.08.019. Epub 2019 Sep 1.

PMID:
31707330
31.

Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets.

Cao TH, Jones DJL, Voors AA, Quinn PA, Sandhu JK, Chan DCS, Parry HM, Mohan M, Mordi IR, Sama IE, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Lang CC, Ng LL.

Eur J Heart Fail. 2020 Jan;22(1):70-80. doi: 10.1002/ejhf.1608. Epub 2019 Nov 6.

PMID:
31692186
32.

Telomere length tracking in children and their parents: implications for adult onset diseases.

Benetos A, Verhulst S, Labat C, Lai TP, Girerd N, Toupance S, Zannad F, Rossignol P, Aviv A.

FASEB J. 2019 Dec;33(12):14248-14253. doi: 10.1096/fj.201901275R. Epub 2019 Oct 25.

PMID:
31652401
33.

Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial.

Monzo L, Ferreira JP, Abreu P, Szumski A, Böhm M, McMurray JJV, Pitt B, Swedberg K, van Veldhuisen DJ, Girerd N, Vincent J, Zannad F, Rossignol P.

J Hypertens. 2020 Mar;38(3):420-425. doi: 10.1097/HJH.0000000000002275.

PMID:
31584516
34.

Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.

Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Anker SD, Zannad F; EMPEROR-Reduced Trial Committees and Investigators.

Eur J Heart Fail. 2019 Oct;21(10):1270-1278. doi: 10.1002/ejhf.1536. Epub 2019 Jul 16.

PMID:
31584231
35.

Arterial Remodeling and Dysfunction in the ZSF1 Rat Model of Heart Failure With Preserved Ejection Fraction.

Leite S, Cerqueira RJ, Ibarrola J, Fontoura D, Fernández-Celis A, Zannad F, Falcão-Pires I, Paulus WJ, Leite-Moreira AF, Rossignol P, López-Andrés N, Lourenço AP.

Circ Heart Fail. 2019 Jul;12(7):e005596. doi: 10.1161/CIRCHEARTFAILURE.118.005596. Epub 2019 Jul 1.

PMID:
31525070
36.

Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.

Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M; EMPEROR-Preserved Trial Committees and Investigators.

Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16.

PMID:
31523904
37.

Eplerenone in patients with myocardial infarction and "mid-range" ejection fraction: An analysis from the EPHESUS trial.

Ferreira JP, Rossello X, Pitt B, Rossignol P, Zannad F.

Clin Cardiol. 2019 Nov;42(11):1106-1112. doi: 10.1002/clc.23261. Epub 2019 Sep 3.

38.

Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure.

Coiro S, Girerd N, Sharma A, Rossignol P, Tritto I, Pitt B, Pfeffer MA, McMurray JJV, Ambrosio G, Dickstein K, Moss A, Zannad F.

Eur J Heart Fail. 2019 Oct;21(10):1248-1258. doi: 10.1002/ejhf.1541. Epub 2019 Sep 2.

PMID:
31476097
39.

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees.

N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.

PMID:
31475794
40.

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.

Mehra MR, Vaduganathan M, Fu M, Ferreira JP, Anker SD, Cleland JGF, Lam CSP, van Veldhuisen DJ, Byra WM, Spiro TE, Deng H, Zannad F, Greenberg B.

Eur Heart J. 2019 Nov 21;40(44):3593-3602. doi: 10.1093/eurheartj/ehz427.

41.

World Heart Federation Roadmap for Heart Failure.

Ferreira JP, Kraus S, Mitchell S, Perel P, Piñeiro D, Chioncel O, Colque R, de Boer RA, Gomez-Mesa JE, Grancelli H, Lam CSP, Martinez-Rubio A, McMurray JJV, Mebazaa A, Panjrath G, Piña IL, Sani M, Sim D, Walsh M, Yancy C, Zannad F, Sliwa K.

Glob Heart. 2019 Sep;14(3):197-214. doi: 10.1016/j.gheart.2019.07.004. Review. No abstract available.

PMID:
31451235
42.

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.

Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CSP; ASIAN-HF investigators, Voors AA.

Lancet. 2019 Oct 5;394(10205):1254-1263. doi: 10.1016/S0140-6736(19)31792-1. Epub 2019 Aug 22.

PMID:
31447116
43.

Heart failure around the world.

Tromp J, Ferreira JP, Janwanishstaporn S, Shah M, Greenberg B, Zannad F, Lam CSP.

Eur J Heart Fail. 2019 Oct;21(10):1187-1196. doi: 10.1002/ejhf.1585. Epub 2019 Aug 16. Review.

PMID:
31419004
44.

Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.

Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, Lefkowitz MP, Shi VC, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV, Solomon SD; PARAGON-HF Investigators.

JACC Heart Fail. 2019 Oct;7(10):862-874. doi: 10.1016/j.jchf.2019.05.015. Epub 2019 Jul 10.

PMID:
31302043
45.

Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction.

Hall TS, von Lueder TG, Zannad F, Rossignol P, Duarte K, Chouihed T, Solomon SD, Dickstein K, Atar D, Agewall S, Girerd N; High-Risk Myocardial Infarction Database Initiative investigators.

Am Heart J. 2019 Sep;215:83-90. doi: 10.1016/j.ahj.2019.06.004. Epub 2019 Jun 12.

PMID:
31291604
46.

Chest X-ray quantification of admission lung congestion as a prognostic factor in patients admitted for worsening heart failure from the ICALOR cohort study.

Kobayashi M, Bercker M, Huttin O, Pierre S, Sadoul N, Bozec E, Chouihed T, Ferreira JP, Zannad F, Rossignol P, Girerd N.

Int J Cardiol. 2020 Jan 15;299:192-198. doi: 10.1016/j.ijcard.2019.06.062. Epub 2019 Jun 26.

PMID:
31281047
47.

The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.

Santema BT, Chan MMY, Tromp J, Dokter M, van der Wal HH, Emmens JE, Takens J, Samani NJ, Ng LL, Lang CC, van der Meer P, Ter Maaten JM, Damman K, Dickstein K, Cleland JG, Zannad F, Anker SD, Metra M, van der Harst P, de Boer RA, van Veldhuisen DJ, Rienstra M, Lam CSP, Voors AA.

Clin Res Cardiol. 2019 Jul 1. doi: 10.1007/s00392-019-01513-y. [Epub ahead of print]

PMID:
31263996
49.

Erratum to 'The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions' [Eur J Heart Fail 2018;20:963-972].

Ambrosy AP, Mentz RJ, Fiuzat M, Cleland JGF, Greene SJ, O'Connor CM, Teerlink JR, Zannad F, Solomon SD.

Eur J Heart Fail. 2019 Jun;21(6):819. doi: 10.1002/ejhf.1480. Epub 2019 May 9. No abstract available.

PMID:
31222927
50.

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.

Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C.

Circ Heart Fail. 2019 Jun;12(6):e005875. doi: 10.1161/CIRCHEARTFAILURE.118.005875. Epub 2019 Jun 5.

PMID:
31163986

Supplemental Content

Loading ...
Support Center